Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Location: United States, California, South San Francisco
Member count: 501-1000
Founded date: 2011
Investors 3
Mentions in press and media 20
| Date | Title | Description | Source |
| 05.08.2022 | Pfizer in talks to buy sickle cell drug maker Global Blood T... | With billions of dollars from the covid vaccine windfall, pharmaceutical giant Pfizer is reportedly ... | techstartu... |
| 20.12.2021 | Global Blood Therapeutics - U.S. FDA Approves Supplemental N... | SOUTH SAN FRANCISCO, Calif. - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the U.S.... | marketscre... |
| 17.12.2021 | U.S. FDA Approves Supplemental New Drug Application for Expa... | New dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the r... | marketscre... |
| 17.12.2021 | Global Blood Therapeutics : U.S. FDA Approves Supplemental N... | U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) ... | marketscre... |
| 17.12.2021 | GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion fo... | European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta w... | globenewsw... |
| 17.12.2021 | GBT's Oxbryta® (voxelotor) Receives Positive CHMP Opinion fo... | European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta w... | marketscre... |
| 13.12.2021 | GBT Presents Positive Results from Phase 1 Study of GBT02160... | GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a mu... | marketscre... |
| 13.12.2021 | Global Blood Therapeutics : Press Release, dated December 13... | GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease a... | marketscre... |
| 30.10.2021 | GBT Mourns the Loss of Sickle Cell Warrior Hertz Nazaire | PDF Version SOUTH SAN FRANCISCO, Calif. - October 29, 2021 - Global Blood Therapeutics, Inc. (GBT) ... | marketscre... |
| 08.09.2021 | Global Blood Therapeutics : U.S. FDA Accepts for Priority Re... | SOUTH SAN FRANCISCO - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced that the U.S. Fo... | marketscre... |
Show more